SCHEMBL17520378

SCHEMBL17520378

COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 16/20 0.80
▸ KDR P35968 5/20 0.80
▸ ERBB2 P04626 3/20 0.80
▸ EPHB4 P54760 2/20 0.80
▸ FBP1 P09467 2/20 0.80
▸ AURKA O14965 1/20 0.80
▸ INSR P06213 1/20 0.80
▸ PDGFRB P09619 1/20 0.80
▸ FLT4 P35916 1/20 0.80
▸ CLK1 P49759 1/20 0.80
▸ TEK Q02763 1/20 0.80
▸ AURKB Q96GD4 1/20 0.80
▸ EPHA2 P29317 3/20 0.72
▸ GAK O14976 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17557985 1.00 EGFR (0.80) EGFRKDRERBB2EPHB4FBP1
SCHEMBL8933754 0.90 EGFR (0.80) EGFRKDRERBB2EPHB4FBP1
SCHEMBL6187570 0.90 KDR (0.85) EGFRKDRERBB2EPHB4FBP1
SCHEMBL30505605 0.90 EGFR (1.00) EGFRKDRERBB2EPHB4FBP1
SCHEMBL2099106 0.90 EGFR (1.00) EGFRKDRERBB2EPHB4FBP1
Hydrochloric Acid SCHEMBL8810665 0.89 EGFR (0.79) EGFRKDRERBB2EPHB4FBP1
Hydrochloric Acid SCHEMBL27887194 0.89 EGFR (0.98) EGFRKDRERBB2EPHB4FBP1
SCHEMBL6187027 0.89 EGFR (0.77) EGFRKDRERBB2EPHB4FBP1
SCHEMBL4230302 0.88 EGFR (0.67) EGFRKDRERBB2EPHB4FBP1
SCHEMBL8933781 0.88 EGFR (0.68) EGFRKDRERBB2EPHB4FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 — — EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 — — US disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 — — US disclosed
CN-106660970-B Quinazoline derivatives 石药集团中奇制药技术(石家庄)有限公司 2020-07-10 — — CN disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 — — US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 — — US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 — — US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 — — US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 — — EP disclosed
WO-2016023330-A1 QUINAZOLINE DERIVATIVE 石药集团中奇制药技术(石家庄)有限公司 2016-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885ERBB2 2622/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885ERBB2 2622/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885ERBB2 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback